Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Iran J Kidney Dis ; 12(5): 315-318, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30367025

ABSTRACT

Two-thirds of complement C3 glomerulopathy (C3G) recur after transplantation and commonly cause graft loss. There is not a standard treatment protocol for these cases. We present a kidney transplant patient with recurrent C3G who was successfully treated with eculizumab. Nephrotic proteinuria and hematuria occurred and creatinine levels increased after transplantation. A graft biopsy revealed recurrent C3G. The patient was administered 250 mg pulse methylprednisolone for 3 days and had 9 sessions of plasmapheresis. Since elevated creatinine levels and proteinuria persisted, eculizumab was instituted. A complete remission was observed after 9-month maintenance eculizumab treatment. Eculizumab may be a potentially effective option in kidney transplant patients with recurrent C3G unresponsive to other treatment modalities.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Complement C3/metabolism , Glomerulonephritis/blood , Glomerulonephritis/drug therapy , Kidney Glomerulus/pathology , Creatinine/blood , Hematuria/etiology , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Proteinuria/etiology , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL